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Abstract
Introduction: Acute kidney injury (AKI) occurs frequently after abdominal aortic surgery and there is currently no effective marker able to detect 
early onset. The aim of this study is to evaluate the ability of neutrophil gelatinase-associated lipocalin (NGAL) to early identify the development of 
acute renal damage in patients undergoing endovascular aneurysm repair (EVAR) or open aortic repair (OAR).
Materials and methods: Serial samples of blood and urine were obtained from 25 patients undergoing both EVAR and OAR. Seven male subjects 
with AKI and 18 subjects with no-AKI (17 males, 1 female) were included in the study. We determined concentrations of serum creatinine (sCr) and 
urinary, serum and whole blood NGAL (uNGAL, sNGAL, bNGAL) collected at baseline, and after 4 and 18 hours. AKI was defined according to the RIFLE 
criteria (risk, injury, failure, loss of kidney function, and end-stage kidney disease): increase by 50% in sCr or reduction of at least 25% of estimated 
glomerular filtration rate (eGFR) from baseline.
Results: Seven patients developed AKI in the stage Risk. There was no significant difference in sNGAL concentrations in the AKI group as compared 
to no-AKI group. However, the uNGAL/uCreatinine ratio and bNGAL concentrations were significantly higher after 18 hours in the AKI group (no-AKI 
1.69 (0.91 - 2.47) vs AKI 3.2 (2.08 - 5.92) ng/mg for uNGAL/uCreatinine ratio, P = 0.036; and no-AKI 83 (59 - 131) vs AKI 164 (126 – 263) ng/mL for 
bNGAL, P = 0.029).
Conclusions: Our results suggest that uNGAL, sNGAL and bNGAL, after abdominal aortic surgery, are not suitable as early biomarkers of AKI.
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Cardiovascular surgery is considered by the Ameri-
can Heart Association (AHA/ACC) as a major risk 
procedure for the development of cardiopulmo-
nary and renal complications. In particular, acute 
renal failure is quite common in patients undergo-
ing endovascular aneurysm repair (EVAR) or open 
aortic repair (OAR). A transient or permanent re-
duction of renal function following major vascular 
surgery is described in a range of between 1 and 
28%. In particular, a retrospective study showed a 
greater incidence of acute kidney injury (AKI) in 
patients undergoing OAR (26.3%) compared to 
EVAR (5.5%) (1).
Despite the progress made in recent years in un-
derstanding acute renal failure pathogenesis, 
many therapeutic interventions have proved inef-
fective (2). This failure is partly determined by the 
lack of a sensitive and specific renal marker that al-
lows an early diagnosis and therefore a timely 
treatment of the disease.
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Recently, scientists have focussed on neutrophil 
gelatinase-associated lipocalin (NGAL), a 25 kDa 
glycoprotein of the lipocalin superfamily. It is nor-
mally expressed in low concentrations in various 
human tissues and it is induced in the kidney early 
after ischemic or nephrotoxic damage. Neutrophil 
gelatinase-associated lipocalin has proven to be 
an early marker of AKI in paediatric and adult pa-
tients undergoing cardiac surgery (3).
Assuming that there is an increase in NGAL at 4 
hours from baseline, the aim of this pilot study is 
to evaluate the ability of NGAL protein, measured 
in serum, whole blood and urine samples, to early 
identify the development of acute renal damage 
in patients undergoing EVAR or OAR. The choice of 
these matrices is dictated by the need to compare 
the reliability of a point of care with respect to oth-
er commercially available techniques.
Materials and methods
Subjects
A cross-sectional study of diagnostic accuracy was 
conducted at IRCCS Policlinico San Donato. During 
the study period (October 2015 - October 2016), 25 
patients (24 male and 1 female) were hospitalized 
in the Vascular Surgery Department for EVAR or 
OAR. They were monitored during the postopera-
tive period for possible onset of AKI defined ac-
cording to the RIFLE criteria (risk, injury, failure, loss 
of kidney function, and end-stage kidney disease). 
The latter is based on increased serum creatinine 
(sCr) by 1.5 times or decreased estimated glomeru-
lar filtration rate (eGFR) by at least 25% with re-
spect to the baseline values (4). Subjects who did 
not develop AKI (N = 18) were included in the no-
AKI group while subjects who reported a serum 
creatinine increase by 1.5 times or an eGFR 25% 
lower than baseline were included in the AKI 
group (N = 7). NGAL protein measurements were 
performed and compared with traditional renal 
function markers, i.e. sCr and eGFR calculated us-
ing the Modification of Diet in Renal Disease study 
equation (MDRD) formula (5). For each subject, 
whole blood, serum and urine samples were col-
lected in three phases defined by the protocol. 
The baseline sample was the blood and urine sam-
pling performed prior to surgery, while the subse-
quent sampling was performed at 4 and 18 hours 
from baseline, which is the time of abdominal 
clamping in the case of traditional intervention or 
the last administration of contrast media in the 
case of endovascular exclusion.
Urine sample was used for creatinine assay and 
then, after centrifugation at 400xg for 5 minutes, 
the supernatant was separated in 10 mL aliquots 
and stored at - 80 °C for the NGAL assay. Serum 
sample, obtained after centrifugation at 1000xg 
for 10 minutes, was used for the creatinine assay 
and then it was stored at - 80 °C until NGAL as-
sayed. Whole blood sample was used immediately 
for NGAL assay by a rapid-point-of-care fluores-
cence immunoassay. Serum sample was collected 
in plastic micronized silica particles tube (4 mL, 
13x75 mm, ref number 368813) and whole blood 
sample was collected in a tube (2 mL, 13x75 mm, 
ref number 367836) with tripotassium salt of ethyl-
enediaminetetraacetic acid (K3EDTA) as anticoagu-
lant (Becton, Dickinson and Company, Franklin 
Lakes, USA).
The study protocol was approved by “Comitato 
Etico Indipendente (C.E.I.) dell’Azienda Socio Sani-
taria Territoriale (A.S.S.T.) Melegnano e della Mar-
tesana”. All subjects signed the informed consent 
and each procedure was conducted in accordance 
with the 1964 Helsinki Declaration and subse-
quent amendments (last amendment October 
2013). For both groups, inclusion criteria were ab-
dominal aortic aneurysm, age > 18 years and 
signed informed consent. Exclusion criteria were 
the extension of the chorea aura aneurysm, pre-
existing chronic renal failure defined by the Na-
tional Kidney Foundation/Kidney Disease Out-
comes Quality Initiative (NKF/KDOQI) guidelines 
and age > 80 years.
Methods
Serum creatinine (intra-assay coefficient of varia-
tion (CV) = 1.4%) and urine creatinine (intra-assay 
CV = 1.4%) were measured using Roche Cobas 
C501 platform (Roche Diagnostics GmbH, Man-
nheim, Germany). Serum creatinine assay is stand-
ardized by tracing reference materials to Isotope 
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Dilution Mass Spectrometry (IDMS). Urinary NGAL 
(uNGAL) concentrations were determined by Ab-
bott ARCHITECT i1000SR® analyzer (Abbott Diag-
nostics GmbH, Wiesbaden, Germany) using an im-
munological chemiluminescence microparticle 
capture (CMIA) assay (intra-assay CV = 3.2%).
Concentrations of NGAL in whole blood samples 
(bNGAL) were determined by Triage® NGAL Test, a 
point-of-care rapid fluorescence immunoassay 
performed on a Triage Meter analyser (Biosite In-
corporated, San Diego, California) (intra-assay CV 
= 12.8%). Serum NGAL (sNGAL) concentrations 
were determined by a Quantikine® Enzyme-Linked 
Immunosorbent Assay (ELISA) Human Lipocalin-2/
NGAL Immunoassay (R&D Systems a Bio-techne 
brand, Inc., Minneapolis, USA) using a direct im-
munoenzymatic assay (ELISA sandwich) (intra-as-
say CV = 3.7%). All CVs are those declared by man-
ufacturers.
Statistical analysis
The results are reported as median and interquar-
tile range (IQR) for continuous variables. Mann-
Whitney U-test was used to compare continuous 
variables between the two groups observed. The 
discriminating capacity of markers was assessed 
by building the Receiver Operating Characteristic 
(ROC) curve. A P-value of < 0.05 was considered 
statistically significant. All statistical analyses were 
performed using the SPSS Statistics program, ver-
sion 21.0 (IBM, Chicago, USA).
Results
A total of 25 patients were enrolled in the study. 
According to the RIFLE criteria, 7 developed AKI 
within the Risk category while 18 subjects were in-
cluded in the no-AKI group. Serum creatinine con-
centrations both prior to intervention and at 4 
hours showed no significant differences between 
no-AKI and AKI patients (at baseline: no-AKI = 72 
(64 – 84) vs AKI = 90 (72 – 95) µmol/L; P = 0.115; at 
4h: no-AKI = 72 (59 – 85) vs AKI = 74 (67 – 91) 
µmol/L; P = 0.364). On the contrary, at 18 hours sCr 
concentrations were significantly higher in the AKI 
group with respect to no-AKI group (114 (100 – 
130) µmol/L and 82 (59 – 87), P = 0.001, respective-
ly). The results of uNGAL, sNGAL and bNGAL as-
says are summarized in Table 1. A ROC curve analy-
sis was performed to demonstrate the capability 




(N = 7) P
uNGAL/uCr ratio (ng/mg)
baseline 1.18 (0.69 – 3.17) 0.84 (0.61 - 1.31) 0.380
4h 2.25 (1.14 – 4.55) 1.97 (1,89 - 4.12) 0.739
18h 1.69 (0.91 - 2.47) 3.20 (2.08 - 5.92) 0.035
bNGAL (ng/dL)
baseline 59 (59 - 74) 60 (59 – 118) 0.580
4h 64 (59 – 105) 102 (82 – 144) 0.101
18h 83 (59 – 131) 164 (127 - 201) 0.029
sNGAL (ng/dL)
baseline 138 (64 – 188) 125 (80 – 161) 0.931
4h 174 (85 - 215) 173 (140 – 226) 0.714
18h 137 (98 – 217) 185 (153 – 226) 0.429
The results are expressed as median and IQR. P < 0.05 was considered statistically significant.
NGAL - neutrophil gelatinase-associated lipocalin. uNGAL - urinary NGAL. bNGAL - whole blood NGAL. sNGAL - serum NGAL. uCr - 
urinary creatinine. AKI - acute kidney injury.
Table 1. Concentrations of uNGAL/uCr ratio, bNGAL and sNGAL at different time points
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Figure 1. ROC curves for sCreatinine. 
Panel A: sCreatinine at 4 h did not discriminate between patients without renal disease following surgery compared to those with 
AKI (AUC (95% CI) = 0.62 (0.36 - 0.89); P = 0.348). Panel B: sCreatinine performed at 18 h shows that it is possible to separate the two 
patient groups (AUC (95% CI) = 0.94 (0.85 - 1.04); P = 0.001). sCreatinine - serum creatinine. AKI - acute kidney injury. AUC - area under 
curve.
Figure 2. ROC curves for uNGAL/uCreatinine ratio. 
Panel A: uNGAL/uCreatinine ratio at 4 h did not discriminate between patients without renal disease following surgery compared 
to those with AKI (AUC (95% CI) = 0.55 (0.30 - 0.80); P = 0.716). Panel B: uNGAL/uCreatinine ratio performed at 18 h shows that it is 
possible to separate the two patient groups (AUC (95% CI) = 0.80 (0.57 - 1.02); P = 0.033). uCreatinine - urinary creatinine. AKI - acute 
kidney injury. uNGAL - urinary neutrophil gelatinase-associated lipocalin. AUC - area under curve.
who developed AKI after EVAR or OAR. The results 
of the ROC curve for serum creatinine, ratio uN-
GAL/uCreatinine and bNGAL are described in Fig-
ures 1-3. Serum NGAL ROC curve shows that the 
NGAL marker on serum samples is unable to dis-
criminate between AKI and no-AKI patients.
Discussion
From the analysis of the results we can suggest 
that the NGAL protein in the three different matri-
ces studied is not an early biomarker of AKI. The 
18-hour sCr assay showed a statistically significant 
increase in the AKI group although we would have 
expected a significant increase not earlier than 24 
hours from baseline (6). The statistical analysis of 
sNGAL assays by ELISA did not show statistically 
significant differences between AKI and no-AKI 
group. At 18 hours we observed statistically signifi-
cant difference in uNGAL/uCreatinine ratio and in 
bNGAL concentrations between the two groups 
but we would have expected a significant increase 
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According to our knowledge there are not many 
studies that have examined the role of NGAL in 
predicting the development of AKI in similar pa-
tients’ population. In 2017 Noorani et al. assessed 
changes in urinary biomarkers, including NGAL, in-
terleukin 18 (IL-18) and sCr in patients undergoing 
EVAR. A significant increase in NGAL and IL-18 was 
observed at 6 hours after the procedure while sCr 
concentration rose only after 24 hours (7). Brink-
man et al. investigated the ability of NGAL in pre-
dicting AKI in patient undergoing OAR. They dem-
onstrated that postoperative urinary NGAL has the 
ability to predict the development of a subse-
quent AKI (8). In recent years, other emerging uri-
nary biomarkers have also been considered to 
identify early onset of AKI in subjects undergoing 
EVAR and OAR. In particular, in 2014 Pirgakis et al. 
have assessed the ability of urinary cystatin C (uCy-
sC) to detect renal dysfunction earlier than serum 
creatinine. It has been observed that in the AKI 
group the urinary cystatin C concentrations at 6 
hours were significantly higher than no-AKI pa-
tients (9). Another promising candidate as kidney 
injury biomarker is the liver-type fatty-acid-bind-
ing protein (L-FABP). In 2016 Obata et al. described 
urinary L-FABP as an early AKI marker in the same 
patient population. In fact, a significant increase in 
urinary L-FABP in the AKI group was observed at 4 
h for patients undergoing EVAR and at 2 h after 
aortic cross-clamping (AXC) for patients undergo-
ing OAR (10). 
In our study ROC curve analysis for different bio-
logical matrices suggests that urine and whole 
blood NGAL assay can be a good diagnostic test at 
18-hour from time 0 but it is not an early biomark-
er of AKI. The low number of analysed samples 
limits the power of the analysis and does not allow 
for a cut-off value in the diagnosis of AKI.
Our study presents some limitations. First limita-
tion is its small sample size, although the duration 
of our recruitment was 12 months, so we want to 
recruit a larger sample sizes to confirm our find-
ings. Second, AKI is detected according to RIFLE 
criteria that represent an imperfect estimate of the 
kidney function and we do not consider other sur-
rogates like survival, intra-hospital complications 
and decline of kidney function in long-term. How-
ever, we think the study is interesting because 
there are not many papers in the literature that 
take into account similar patients.
In conclusion, contrary to the principal findings in 
literature, our data do not allow us to state that 
NGAL is an early marker of AKI in patients under-
going EVAR and OAR. 
Figure 3. ROC curves for bNGAL.
Panel A: bNGAL at 4 h did not discriminate between patients without renal disease following surgery compared to those with AKI 
(AUC (95% CI) = 0.71 (0.49 - 0.94); P = 0.102). Panel B: bNGAL performed at 18 h shows that it is possible to separate the two patient 
groups (AUC (95% CI) = 0.81(0.63 - 0.99); P = 0.028). bNGAL - whole blood neutrophil gelatinase-associated lipocalin. AKI - acute kid-
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